Donafenib for Recurrent Cervical Cancer

NCT05310331 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Targeted Therapy
Chemotherapy
Recurrent Cervical Carcinoma
Metastatic Cervical Carcinoma
Persistent Advanced Cervical Carcinoma
Survival Outcomes
Adverse Effect

Interventions

COMBINATION_PRODUCT: Donafenib combined with paclitaxel and platinum ± PD-1 antibody

Sponsor

Lei Li